Cargando…
Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications
Traditionally, guidelines divide patients into primary and secondary prevention for atherosclerotic cardiovascular disease (ASCVD) risk management. However, the modern understanding of the biological progression of atherosclerosis is inconsistent with this binary approach. Therefore, a new approach...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826921/ https://www.ncbi.nlm.nih.gov/pubmed/36632617 http://dx.doi.org/10.1016/j.ajpc.2022.100456 |
_version_ | 1784866963410911232 |
---|---|
author | Blaha, Michael J. Abdelhamid, Magdy Santilli, Francesca Shi, Zhongwei Sibbing, Dirk |
author_facet | Blaha, Michael J. Abdelhamid, Magdy Santilli, Francesca Shi, Zhongwei Sibbing, Dirk |
author_sort | Blaha, Michael J. |
collection | PubMed |
description | Traditionally, guidelines divide patients into primary and secondary prevention for atherosclerotic cardiovascular disease (ASCVD) risk management. However, the modern understanding of the biological progression of atherosclerosis is inconsistent with this binary approach. Therefore, a new approach demonstrating both atherosclerosis and ASCVD risk as a continuum is needed to give clinicians a framework for better matching risk and intensity of therapy. Advances in coronary imaging have most clearly brought this problem into view, as for example coronary artery calcium (CAC) scoring has shown that some individuals in the primary prevention have equal or higher ASCVD risk as certain subgroups in secondary prevention. This article introduces “advanced subclinical atherosclerosis” as a new and distinct clinical group that sits between the traditional groups of primary and secondary prevention. Importantly, this article also introduces a new graphic to visualize this intermediate population that is explicitly based on plaque burden. The aim of the graphic is both to educate and to allow for better identification of a patient's cardiovascular risk and guide more effective risk-based management. |
format | Online Article Text |
id | pubmed-9826921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-98269212023-01-10 Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications Blaha, Michael J. Abdelhamid, Magdy Santilli, Francesca Shi, Zhongwei Sibbing, Dirk Am J Prev Cardiol Commentary Traditionally, guidelines divide patients into primary and secondary prevention for atherosclerotic cardiovascular disease (ASCVD) risk management. However, the modern understanding of the biological progression of atherosclerosis is inconsistent with this binary approach. Therefore, a new approach demonstrating both atherosclerosis and ASCVD risk as a continuum is needed to give clinicians a framework for better matching risk and intensity of therapy. Advances in coronary imaging have most clearly brought this problem into view, as for example coronary artery calcium (CAC) scoring has shown that some individuals in the primary prevention have equal or higher ASCVD risk as certain subgroups in secondary prevention. This article introduces “advanced subclinical atherosclerosis” as a new and distinct clinical group that sits between the traditional groups of primary and secondary prevention. Importantly, this article also introduces a new graphic to visualize this intermediate population that is explicitly based on plaque burden. The aim of the graphic is both to educate and to allow for better identification of a patient's cardiovascular risk and guide more effective risk-based management. Elsevier 2022-12-24 /pmc/articles/PMC9826921/ /pubmed/36632617 http://dx.doi.org/10.1016/j.ajpc.2022.100456 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Blaha, Michael J. Abdelhamid, Magdy Santilli, Francesca Shi, Zhongwei Sibbing, Dirk Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications |
title | Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications |
title_full | Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications |
title_fullStr | Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications |
title_full_unstemmed | Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications |
title_short | Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications |
title_sort | advanced subclinical atherosclerosis: a novel category within the cardiovascular risk continuum with distinct treatment implications |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826921/ https://www.ncbi.nlm.nih.gov/pubmed/36632617 http://dx.doi.org/10.1016/j.ajpc.2022.100456 |
work_keys_str_mv | AT blahamichaelj advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications AT abdelhamidmagdy advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications AT santillifrancesca advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications AT shizhongwei advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications AT sibbingdirk advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications |